Osteoclast Stimulatory Transmembrane Protein (OC-STAMP) is a Promising Molecular Prognostic Indicator for Multiple Myeloma

Zi-Long Wang,Yang Liu,Ya-Lan Zhou,Jin-Lan Li,Qiu-Yu Sun,Li-Xin Wu,Lei Wen,Yue-Yun Lai,Yan-Rong Liu,Ying-Jun Chang,Hong-Xia Shi,Kai-Yan Liu,Xiao-Jun Huang,Jin Lu,Guo-Rui Ruan
DOI: https://doi.org/10.1111/ejh.13425
2020-01-01
European Journal Of Haematology
Abstract:Background Currently, the prognostic stratification and therapeutic evaluation systems for multiple myeloma (MM) lack specific molecular indicators. OC-STAMP is a new gene and is also highly expressed in MM. Methods A total of 160 MM patients have been investigated with both quantitative reverse transcription PCR (RT-qPCR), flow cytometry (FCM) and cytogenetic FISH on the same mononuclear cells isolated from bone marrow specimens. Results We found that OC-STAMP mRNA levels were significantly higher in newly diagnosed cases of MM than in healthy donors (median, 0.52% vs. 0.02%, P < .001). Moreover, the changes in the OC-STAMP mRNA levels paralleled the disease stages and minimal residual disease, as detected by FCM. Furthermore, we found that patients with high OC-STAMP mRNA levels were more likely to develop >= 3 bone lesions, be diagnosed with Durie-Salmon stages III, and have the P53 (17p13) deletion. In addition, advanced stage patients with high OC-STAMP mRNA levels had a lower 4-year progression-free survival (5.6% vs. 22.9%, P = .0055) and a worse 4-year overall survival (25.8% vs. 48.8%, P = .0137) compared to patients with low mRNA levels of this indicator. Conclusions OC-STAMP may be a promising molecular indicator to monitor treatment effects and participate in the prognostic stratification of MM.
What problem does this paper attempt to address?